An efficient procedure for the synthesis of 2-aminothiazoles via DBH-mediated oxidative cyclization of styrenes and thioureas is reported. Various alkenes were successfully transformed to the corresponding 2-aminothiazoles in yields of 10–81% via a two-step one-pot manner using DBH as both the bromine source and oxidant. The method can be readily carried out in gram-scale and successfully applied to
The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.
[EN] 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER<br/>[FR] 2-ACYLAMINOTHIAZOLES POUR LE TRAITEMENT DU CANCER
申请人:UNIV MILANO BICOCCA
公开号:WO2015001024A1
公开(公告)日:2015-01-08
The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.
variety of terminalalkenes were converted to the corresponding amides in yields of 25 to 86% in water via treatment with 1,3-dibromo-5,5-dimethylhydantoin, followed by reaction with molecular iodine and aq. NH3 (or amine) in one pot. This metal- and organic solvent-free protocol is not only suitable for styrene derivatives, but also, for the first time, works well on terminal aliphatic alkenes.
New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
申请人:Laboratorios Almirall, S.A.
公开号:EP2108641A1
公开(公告)日:2009-10-14
This invention is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I)
to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.